Because cancer treatment relies heavily on DNA damaging agents, including radiation and chemotherapeutic drugs, we hypothesized that Mastl upregulation renders cancer cells resistant to treatment, and thereby, increases the risk of tumor recurrence and patient mortality. This evidence concerns the gene MASTL and neoplasm.